News summary

Humacyte’s bioengineered bypass vessel gets first human test

Source: Longevity Technology • Published: 17 Nov 2026, 17:27

Summarized by Masters of Longevity from Longevity Technology.

A ten‑patient trial began testing a manufactured vascular graft for bypass.

Humacyte’s bioengineered bypass vessel gets first human test
Key Takeaways
  • Humacyte started a ten‑patient trial of an off‑the‑shelf graft.
  • The graft is intended to replace harvesting a patient’s leg vein.
  • Human efficacy and safety remain unproven in this early trial.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.